Atyr pharma inc (LIFE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Mar'14
Cash flows from operating activities:
Consolidated net income (loss)

1,752

-6,133

-5,645

-5,848

-6,137

-6,322

-7,114

-10,412

-10,667

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-13,405

-

-13,819

-15,383

-16,087

-16,493

-11,329

-11,080

-9,071

-6,093

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization

157

157

154

157

167

179

191

192

184

161

152

174

226

221

222

224

233

226

224

210

209

203

Issuance of common stock for technology

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,411

-

Stock-based compensation

423

425

278

509

571

602

690

1,211

928

3,135

1,189

1,183

1,277

1,152

1,224

1,373

1,280

2,387

1,050

816

603

-

Debt discount accretion and non-cash interest expense

129

151

169

186

201

223

242

420

81

176

168

209

37

-

-

-

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

146

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

54

-

70

40

128

70

Change in fair value of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

48

-77

30

Accretion of discount of available-for-sale investment securities

24

39

45

94

106

48

94

55

64

99

0

-39

-74

-35

-99

-133

-264

-310

-287

-188

-4

-3

Amortization of right-of-use assets

201

195

187

180

169

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

-6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

0

0

-49

-81

-81

-80

-78

-76

-76

-75

-73

-71

-66

Changes in operating assets and liabilities
Collaboration receivable

-

-

-

-

630

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-236

-325

-370

458

-97

-428

16

-238

40

41

-96

70

-776

-516

1,331

464

-858

-526

-305

1,310

187

-94

Accounts payable and accrued expenses

-578

321

657

169

-985

81

-359

-781

-999

-2,164

691

1,376

-2,792

-1,044

-1,035

164

983

3,226

1

-48

765

-732

Contract liability

-65

-144

-184

-94

630

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

-179

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

2,058

-4,916

-4,253

-4,821

-6,023

-4,839

-6,460

-9,187

-10,577

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-13,888

-

-14,687

-13,988

-12,491

-9,835

-9,467

-11,209

-6,286

-6,345

Purchases of property and equipment

166

41

28

0

10

9

36

51

498

160

441

449

262

46

64

176

314

119

382

40

123

211

Purchases of available-for-sale investment securities

3,081

5,979

4,588

16,085

13,995

16,924

0

15,387

7,988

12,370

53,813

0

11,489

1,845

4,320

11,930

9,994

-

-

-

-

-

Maturities of available-for-sale investment securities

14,650

4,800

11,800

18,350

10,650

14,800

20,765

22,600

19,900

9,000

14,497

11,700

16,150

10,493

11,072

15,951

24,700

-

-

-

-

-

Proceeds from sale of property and equipment

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

11,406

-1,220

7,209

2,291

-3,355

-2,133

20,729

7,162

11,414

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,397

Maturities of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,950

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

4,399

-

6,688

3,845

14,392

3,904

7,238

-84,963

1,827

-5,608

Proceeds from issuance of preferred stock for cash, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

31

29,318

46,299

-

Costs paid in connection with initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

501

-

Proceeds from issuance of common stock through option exercises

-

-

-

-

-

-

-

-

8

-

14

22

1

0

1

8

11

71

0

464

69

13

Proceeds from issuance of common stock through at the market offerings, net of offering costs

-

0

1,878

1,146

1,381

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock through underwritten follow-on offering, net of offering costs

18,779

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments on borrowings

2,000

2,000

2,000

2,000

2,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

16,779

-1,995

-122

4,072

-619

-1,613

-1,994

-639

8

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

30,243

-

-

-

-9,997

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments on loans payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

861

848

838

-

-

-

-

-

Repayments on notes payable to bank

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

815

803

795

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-860

-765

-827

-1,097

-784

104,726

45,072

13

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-2,664

845

-

-6,150

7,015

-9,488

4,056

-8,859

-10,908

1,074

-7,028

-3,013

8,554

40,613

-11,940

Supplemental schedule of noncash investing and financing activities:
Deferred initial public offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,233

-